Mohs Micrographic Surgery
Customize your policy alerts
Sign up for Blue Cross Blue Shield - North Carolina Policy CG-SURG-90 alerts
Get alerted when Policy CG-SURG-90 changes without checking for updates manually.
Monitor payer policy activity
Clinical utilization guideline for Mohs micrographic surgery (MMS) describing when MMS is considered medically necessary or not medically necessary for treatment of skin malignant neoplasms for Blue Cross Blue Shield - North Carolina members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medically Necessary
Mohs micrographic surgery (MMS) is considered medically necessary for basal cell carcinoma, squamous cell carcinoma, and melanoma in situ (including lentigo maligna) when ALL of the following structure/clinical conditions are met:
Less common cutaneous tumors considered medically necessary
Mohs micrographic surgery is considered medically necessary for the following less common cutaneous tumors when the tumor type is confirmed and criteria above (or other specific guidance) are met:
Covered when ALL of the following are met (summary of indications cited)
MMS is considered an option and covered when documentation shows the presence of high‑risk features or scenarios consistent with authoritative guideline (NCCN/AAD/AUC) recommendations; coverage applies when criteria consistent with high‑risk features are present.
Evidence-supported indications and considerations
Evidence summaries and guideline considerations relevant to MMS use in the covered indications:
observational pooled analyses
systematic review of observational studies
observational data; no RCTs
evidence limited; guideline recommends MMS or PDEMA over WLE
selective use per NCCN; no RCTs
Mohs micrographic surgery is not medically necessary when the specific medical necessity criteria described in this policy are not met.
For the procedure and diagnosis codes listed in this policy, Mohs micrographic surgery is not medically necessary when the policy criteria are not met or for diagnoses not listed in the Clinical Indications section; this includes situations where the code describes a procedure or situation designated as not medically necessary in the guideline.
The policy notes that Mohs micrographic surgery is not recommended for primary treatment of invasive cutaneous melanoma when standard clinical margins can be obtained; MMS may be considered selectively for minimally invasive (T1a) melanomas only in anatomically constrained areas where standard margins are not feasible.
Federal and state law, contract language (including definitions and specific coverage provisions/exclusions), and Medical Policy take precedence over Clinical UM Guidelines and must be considered first when determining eligibility for coverage; providers should use the member's contract benefits in effect on the date of service.
Coding (CPT / ICD-10)
| 17311-17312 | Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels |
| 17313-17314 | Mohs micrographic technique for trunk, arms, or legs (first stage and each additional stage) |
| 17315 | Each additional block after the first 5 tissue blocks, any stage |
| C4A.0-C4A.9 | Merkel cell carcinoma (ICD-10 series referenced) |
| C44.00-C44.99 | Other and unspecified malignant neoplasm of skin |
| C49.0-C49.9 | Malignant neoplasm of other connective and soft tissue |
| C51.0-C51.9 | Malignant neoplasm of vulva |
| C60.0-C60.9 | Malignant neoplasm of penis |
| C63.2 | Malignant neoplasm of scrotum |
| C69.60-C69.62 | Malignant neoplasm of orbit |
| C69.80-C69.82 | Malignant neoplasm of overlapping sites of eye and adnexa |
| D03.0-D03.9 | Melanoma in situ |
| C60.0-C60.9 | Malignant neoplasm of penis |
| C63.2 | Malignant neoplasm of scrotum |
| C69.60-C69.62 | Malignant neoplasm of orbit |
| C69.80-C69.82 | Malignant neoplasm of overlapping sites of eye and adnexa |
| D03.0-D03.9 | Melanoma in situ |
| D04.0-D04.9 | Carcinoma in situ of skin [Bowen's disease] |
| D07.1 | Carcinoma in situ of vulva |
| D07.4 | Carcinoma in situ of penis |
| D03.0-D03.9 | Melanoma in situ |
| D04.0-D04.9 | Carcinoma in situ of skin [Bowen's disease] |
| D07.1 | Carcinoma in situ of vulva |
| D07.4 | Carcinoma in situ of penis |
| D07.61 | Carcinoma in situ of scrotum |
| C69.80-C69.82 | Malignant neoplasm of overlapping sites of eye and adnexa |
| Q82.1 | Xeroderma pigmentosum |
| Q87.89 | Other specified congenital malformation syndromes, not elsewhere classified (e.g., basal cell nevus syndrome) |
| D04.0-D04.9 | Carcinoma in situ of skin [Bowen's disease] |
| D07.1 | Carcinoma in situ of vulva |
| D07.4 | Carcinoma in situ of penis |
| D07.61 | Carcinoma in situ of scrotum |
| Q82.1 | Xeroderma pigmentosum |
| Q87.89 | Other specified congenital malformation syndromes (e.g., basal cell nevus syndrome) |
| Z21 | Asymptomatic human immunodeficiency virus [HIV] infection status |
| D07.1 | Carcinoma in situ of vulva |
| D07.4 | Carcinoma in situ of penis |
| D07.61 | Carcinoma in situ of scrotum |
| Q82.1 | Xeroderma pigmentosum |
| Q87.89 | Other specified congenital malformation syndromes, not elsewhere classified (specified as basal cell nevus syndrome) |
| Z21 | Asymptomatic human immunodeficiency virus [HIV] infection status |
| Z85.6 | Personal history of leukemia |
| D07.4 | Carcinoma in situ of penis |
| D07.61 | Carcinoma in situ of scrotum |
| Q82.1 | Xeroderma pigmentosum |
| Q87.89 | Other specified congenital malformation syndromes, not elsewhere classified (specified as basal cell nevus syndrome) |
| Z21 | Asymptomatic human immunodeficiency virus [HIV] infection status |
| Z85.6 | Personal history of leukemia |
| Z85.71-Z85.79 | Personal history of other malignant neoplasms of lymphoid, hematopoietic and related |
| D07.4 | Carcinoma in situ of penis |
| D07.61 | Carcinoma in situ of scrotum |
| Q82.1 | Xeroderma pigmentosum |
| Q87.89 | Other specified congenital malformation syndromes, not elsewhere classified (specified as basal cell nevus syndrome) |
| Z21 | Asymptomatic human immunodeficiency virus [HIV] infection status |
| Z85.6 | Personal history of leukemia |
| Z85.71-Z85.79 | Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues |
| Q82.1 | Xeroderma pigmentosum |
| Q87.89 | Other specified congenital malformation syndromes, not elsewhere classified (specified as basal cell nevus syndrome) |
| Z21 | Asymptomatic human immunodeficiency virus [HIV] infection status |
| Z85.6 | Personal history of leukemia |
| Z85.71-Z85.79 | Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues |
| D07.61 | Carcinoma in situ of scrotum |
| Z92.25 | Personal history of immunosuppression therapy |
| 17311 | Mohs micrographic technique, first stage, head, neck, hands, feet, genitalia (example as listed) |
| 17312 | Mohs micrographic technique, each additional stage, head, neck, hands, feet, genitalia (example as listed) |
| 17313 | Mohs micrographic technique, first stage, trunk, arms, or legs (example as listed) |
| 17314 | Mohs micrographic technique, each additional stage, trunk, arms, or legs (example as listed) |
| Q82.1 | Xeroderma pigmentosum |
| Q87.89 | Other specified congenital malformation syndromes, not elsewhere classified (specified as basal cell nevus syndrome) |
| Z21 | Asymptomatic human immunodeficiency virus [HIV] infection status |
| Z85.6 | Personal history of leukemia |
| Z85.71-Z85.79 | Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues |
| D07.61 | Carcinoma in situ of scrotum |
Provider Actions & Billing Guidance
Verify prior authorization requirement with member's plan
Contact the customer service number on the back of the member's ID card to determine whether review or prior authorization is required for Mohs micrographic surgery; plan adoption of Clinical UM Guidelines and utilization review requirements may vary by plan.
- Plans may choose whether to adopt this Clinical UM Guideline for utilization review.
- Use the member's contract benefits in effect on the date services are rendered to determine coverage.
No explicit prior authorization rule stated in ICD-10 listings
The policy text in the provided ICD-10 sections does not state a universal prior authorization requirement for Mohs surgery; the document primarily lists diagnosis codes rather than a plan-level PA rule.
ICD-10 code lists are not authorization statements
Some document segments contain no prior authorization language and only list diagnosis codes; do not assume authorization is required from these code lists alone.
Reference the policy's ICD-10 diagnosis codes on requests and claims
When requesting authorization or submitting claims, reference the ICD-10 diagnosis codes listed in the policy's ICD-10 sections (examples include D04.0-D04.9, D07.1, D07.4, D07.61, Q82.1, Q87.89, Z21).
- Include the most specific listed ICD-10 code that matches the clinical diagnosis.
- Use the diagnosis codes from the policy's ICD-10 section on both authorization requests and claims when applicable.
Use listed ICD-10 codes when requesting authorization or billing
Include appropriate ICD-10 diagnosis codes from the policy (for example D07.4, D07.61, Q82.1, Q87.89, Z21, Z85.6, Z85.71‑Z85.79) when submitting prior authorization requests or claims for Mohs surgery.
- Select the code(s) that most precisely reflect the lesion/site (eg, D07.4 for carcinoma in situ of penis).
- If multiple relevant codes apply (history, syndrome, status), document and include them as appropriate.
Include documented ICD-10 diagnosis codes on authorization/claim to avoid mismatch denials
Ensure claims use an appropriate ICD-10 diagnosis code from the policy's lists (examples shown include D07.61, Q82.1, Q87.89, Z21, Z85.6, Z85.71‑Z85.79); claims with codes not supported by documentation or the policy section may be at risk for denial.
- Mismatch between claim diagnosis codes and documented clinical findings may trigger denial.
- Include supporting documentation tying the selected ICD-10 code to the lesion and indication.
Document MMS stages and tissue block counts to support coding
Document histology/stage details and tissue block counts consistent with MMS coding: first stage up to 5 tissue blocks, each additional stage up to 5 tissue blocks, and bill additional blocks per‑block as indicated.
- Record the number of stages performed and the number of tissue blocks per stage in operative and pathology notes.
- Ensure billing codes (17311–17315 and per‑block codes) align with documented stages/blocks.
Document alternative treatment options when applicable
Consider alternative treatments when MMS is not indicated or available; options include topical therapies, cryotherapy, curettage and electrodesiccation, radiotherapy, or standard wide local excision depending on clinical scenario and patient preference.
- Document rationale for choosing MMS over (or instead of) alternative modalities when relevant.
- If MMS is not performed, document why an alternative was selected and how it aligns with clinical guidelines.
Coordinate SLNB timing with definitive excision for Merkel cell carcinoma
When sentinel lymph node biopsy (SLNB) is indicated for Merkel cell carcinoma, coordinate SLNB timing with definitive excision; if SLNB is not performed concurrently, perform SLNB prior to definitive excision with exhaustive histologic margin assessment (eg, Mohs) per the policy guidance.
- Coordinate multidisciplinary planning (surgical oncology, dermatologic surgery) to avoid interfering with SLNB.
- Document timing and reasoning for SLNB and relation to definitive excision in the record.
Risk of denial if medical necessity criteria are not met
Services will be considered not medically necessary and may be denied when the medical necessity criteria in the policy are not met; verify that the documented clinical criteria match the policy's indications before submitting authorization or claim.
- If documentation does not support the policy's medically necessary criteria, expect denial.
- Use the policy criteria (anatomic location/size, aggressive features, host factors, etc.) to justify MMS in the record.
Verify contract terms and follow precedence rules before requesting authorization
Federal and State law, contract language, and Medical Policy take precedence over the Clinical UM Guideline; verify member contract benefits effective on the date of service and contact customer service to determine whether utilization review or plan‑specific requirements apply.
- Do not rely solely on this guideline for coverage—confirm member's plan and contract terms.
- Contact the customer service number on the member's card for plan‑specific prior authorization or utilization review procedures.
Confirm plan‑specific utilization review or prior authorization requirements
Clinical UM Guidelines may be used by plans when performing utilization review; contact the customer service number on the member's card to confirm whether the member's plan requires utilization review or prior authorization for Mohs surgery.
- Plan adoption of Clinical UM Guidelines varies—confirm with member's plan.
- If utilization review is required, provide documentation mapped to the guideline criteria.
No step therapy requirements described in this policy
Clinical UM Guidelines and the policy note that no step therapy requirements for Mohs surgery are described in the provided history and policy excerpts; do not apply drug/step therapy processes to surgical authorization based on this document.
- If a plan imposes any stepwise requirements, confirm with customer service—this policy does not specify step therapy.
- Document any required prior treatments only if the plan's utilization review requests them.
Background
Mohs micrographic surgery (MMS) is an outpatient, tissue-sparing staged excision technique in which the surgeon removes skin tissue in successive stages and performs microscopic examination of the surgical margins (mapping, color-coding, and histologic assessment) until margins are clear; it is intended to maximize margin control while preserving normal tissue.
Published systematic reviews and pooled observational studies report low recurrence and high cure rates for MMS in selected tumors: pooled 5‑year cure rate for non‑metastatic SCC treated with MMS was 97.4% (pooled local recurrence ~3%), periocular BCC pooled recurrence after MMS ~2.9% versus 5.9% after wide local excision, pooled recurrence for lentigo maligna / melanoma in situ after MMS was ~1.35%, and single‑arm pooled analyses for dermatofibrosarcoma protuberans showed lower recurrence after MMS (~1.5%) than WLE (~9.4%) though comparative data remain limited.
Definitions
Revision History
This policy and its history were reviewed by MPTAC on 02/15/2024 (most recent recorded MPTAC review) and previously on 02/16/2023; an earlier revision including a typographical correction was recorded on 08/11/2022.
Prior revisions noted in the history include a documented typographical correction to the first medically necessary statement on 08/11/2022, which is recorded in the policy history entries.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.